Systemic lupus erythematosus: a clinical update.
diagnosis
systemic lupus erythematosus
therapeutics
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
11
03
2021
received:
17
10
2020
accepted:
25
04
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease known for its complexity and heterogeneity. Striking diversity can be observed between individual patients, in terms of clinical manifestations, serological abnormalities, disease progression and response to therapy. Furthermore, dysfunction of a broad range of immune pathways underlies disease development and expression. An appreciation of this diversity is vital in order to diagnose accurately and appropriately treat patients with SLE as there is no one-size-fits-all diagnostic test or treatment. Optimal management involves identifying affected organs, assessing severity, differentiating activity from irreversible damage and tailoring immunosuppressive treatment accordingly. Non-pharmacological interventions, attention to disease and treatment-related comorbidities and addressing the significant impact on health-related quality of life are also crucial to maximising patient outcomes.
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1219-1228Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016; 12: 605-20.
Yen EY, Singh RR. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000−2015. Arthritis Rheumatol 2018; 70: 1251-5.
Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.
Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus 2003; 12: 327-31.
Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009; 48: 673-5.
Kiani AN, Strand V, Fang H, Jaranilla J, Petri M. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatology 2013; 52: 1651-7.
Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012; 14: S4.
Felten R, Sagez F, Gavand PE, Martin T, Korganow AS, Sordet C et al. 10 most important contemporary challenges in the management of SLE. Lupus Sci Med 2019; 6: e000303.
Jones SA, Cantsilieris S, Fan H, Cheng Q, Russ BE, Tucker EJ et al. Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus. Sci Rep 2019; 9: 15433.
Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019; 393: 2332-43.
Dorner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393: 2344-58.
Stojan G, Kvit A, Curriero FC, Petri M. A spatiotemporal analysis of organ-specific lupus flares in relation to atmospheric variables and fine particulate matter pollution. Arthritis Rheumatol 2020; 72: 1134-42.
Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1152-8.
Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682-8.
Yeo AL, Le S, Ong J, Connelly K, Ojaimi S, Nim H et al. Utility of repeated antinuclear antibody tests: a retrospective database study. Lancet Rheumatol 2020; 2: e412-7.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997; 40: 1601-11.
Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39.
Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29-36.
Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145-51.
Dima A, Opris D, Jurcut C, Baicus C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus 2016; 25: 1173-9.
Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011; 20: 588-97.
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736-45.
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79: 713-23.
Montes RA, Mocarzel LO, Lanzieri PG, Lopes LM, Carvalho A, Almeida JR. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index: preliminary data and systematic review. Arthritis Rheumatol 2016; 68: 441-8.
Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
Garg M, Mufti N, Palmore TN, Hasni SA. Recommendations and barriers to vaccination in systemic lupus erythematosus. Autoimmun Rev 2018; 17: 990-1001.
Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020; 72: 529-56.
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476-85.
Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2013; 27: 363-75.
Jorge A, McCormick N, Lu N, Zheng Y, Esdaile J, De Vera M et al. Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population. Arthritis Care Res 2020. doi: 10.1002/acr.24255
The Royal College of Ophthalmologists (RCOphth). Hydroxychloroquine and chloroquine retinopathy monitoring. London: RCOphth; 2020. Available from URL: https://www.rcophth.ac.uk/standards-publications-research/clinical-guidelines/
Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 2020; 72: 448-53.
Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu Y-J, Lateef A et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol 2020; 2: e24-30.
Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hié M, Pineton de Chambrun M et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 2020; 79: 339-46.
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 2017; 76: 1575-82.
Golder V, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, Luo S, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol 2019; 1(2).
Dolgin E. Lupus in crisis: as failures pile up, clinicians call for new tools. Nat Biotechnol 2019; 37: 7-8.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71: 1343-9.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383: 1117-28.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020; 382: 211-21.